期刊文献+

Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants

原文传递
导出
摘要 To the Editor:As of January 27,2022,there were 363,062,293 cases and 5,645,884deaths from the COVID-19 pandemic1.The prevalent mutated strains have aggravated the global pandemic2.SARS-Co V-2 is highly mutable,and the mutations on the spike(S)protein resulted in a high transmission of COVID-19 and vaccine breakthrough infection3.For example,there is a notable decrease in neutralizing ability of BNT162b2 vaccination-elicited antibodies against the Delta and other variants4,5,and attenuation of peak viral burden and vaccine effectiveness are reduced with Delta variant6.
出处 《Acta Pharmaceutica Sinica B》 SCIE CAS CSCD 2022年第7期3187-3194,共8页 药学学报(英文版)
基金 the support of the National Key Research and Development Program of China(2021YFE0103100,China) National Natural Science Foundation of China of China(81925035 and 81521005) Shanghai Sci-Tech Innovation Initiative(19431903100,18430740800,China) the Sanofi-SIBS Yong Faculty Award(China) the Youth Innovation Promotion Association(China)。
  • 相关文献

参考文献5

二级参考文献114

  • 1Cheng Cui,Miao Zhang,Xueting Yao,Siqi Tu,Zhe Hou,Valerie Sia Jie En,Xiaoqiang Xiang,Jing Lin,Ting Cai,Ning Shen,Chunli Song,Jie Qiao,Shun Zhang,Haiyan Li,Dongyang Liu.Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model[J].Acta Pharmaceutica Sinica B,2020,10(7):1216-1227. 被引量:5
  • 2Chunting He,Ming Qin,Xun Sun.Highly pathogenic coronaviruses: thrusting vaccine development in the spotlight[J].Acta Pharmaceutica Sinica B,2020,10(7):1175-1191. 被引量:8
  • 3Canrong Wu,Yang Liu,Yueying Yang,Peng Zhang,Wu Zhong,Yali Wang,Qiqi Wang,Yang Xu,Mingxue Li,Xingzhou Li,Mengzhu Zheng,Lixia Chen,Hua Li.Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods[J].Acta Pharmaceutica Sinica B,2020,10(5):766-788. 被引量:73
  • 4[29]Girogiou T,Florin L,Schafer F,et al.2001.Human papillomavirus infection requires cell surface heparan sulfate.J Virol,75 (3):1565-1570.
  • 5[30]Gruenheid S,Gatzke L,Meadows H,et al.1993.Herpes simplex virus infection and propagation in a mouse L cell mutant lacking heparan sulfate proteoglycans.J Virol,67(1):93-100.
  • 6[31]Jacquet A,Haumont M,Chellun D,et al.1998.The varicella zoster virus glyeoprotein B (gB) plays a role in virus binding to cell surface heparan sulfate proteoglycans.Virus Res,53 (2):197-207.
  • 7[32]Jenssen H.2005.Anti herpes simplex virus activity of lactoferrin/lactoferricin-an example of antiviral activity of antimicrobial protein/peptide.Cell Mol Life Sci,62 (24):3002-3013.
  • 8[33]Jenssen H,Andersen J H,Mantzilas D,et al.2004.A wide range of medium-sized,highly cationic,alpha-helical peptides show antiviral activity against herpes simplex virus.Antiviral Res,64 (2):119-126.
  • 9[34]Jenssen H,Andersen J H,Uhlln-Hansen L,et al.2004.Anti-HSV activity of lactoferricin analogues is only partly related to their affinity for heparan sulfate.Antiviral Res,61 (2):101-109.
  • 10[35]Jenssen H,Hamill P,Hancock R E.2006.Peptide antimicrobial agents.Clin Microbiol Rev,19(3):491-511.

共引文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部